Jim Simons Salarius Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.17 - $41.34 $16,354 - $3.98 Million	96,200 Added 17.88%	634,261 $124,000
Q2 2022 Aug 12, 2022	BUY	$0.16 - $0.42 $76,050 - $199,632	475,315 Added 757.52%	538,061 $113,000
Q1 2022 May 13, 2022	SELL	$0.34 - $0.54 $39,390 - $62,561	-115,854 Reduced 64.87%	62,746 $25,000
Q4 2021 Feb 11, 2022	BUY	$0.49 - $1.01 $87,514 - $180,386	178,600 New	178,600 $89,000
Q2 2021 Aug 13, 2021	SELL	$1.02 - $1.52 $242,353 - $361,153	-237,601 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$1.0 - $3.0 $237,601 - $712,803	237,601 New	237,601 $352,000
Q2 2020 Aug 13, 2020	SELL	$0.6 - $1.82 $137,058 - $415,744	-228,431 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$0.56 - $3.82 $94,982 - $647,917	169,612 Added 288.36%	228,431 $155,000
Q4 2019 Feb 13, 2020	BUY	$3.02 - $5.9 $7,852 - $15,340	2,600 Added 4.62%	58,819 $222,000
Q3 2019 Nov 13, 2019	BUY	$5.28 - $20.25 $296,836 - $1.14 Million	56,219 New	56,219 $306,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.73M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.